在2024年前九个月财务业绩电话会议上，专注于医疗皮肤科的制药公司Almirall SA报告净销售额增长近8%至7.28亿欧元，EBITDA增长3%，符合全年指引。公司的生物制剂组合，尤其是Ilumetri，成为重要增长动力，销售额激增25%至约1.53亿欧元。 自2023年12月上市以来，新产品Ebglyss已实现超过2000万欧元的销售额，主要来自德国市场。Almirall在研发方面也取得进展 ...

Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a leading biopharmaceutical firm with a market cap of ...

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

Total European sales in this segment grew by 21.9%, underscoring the company’s expanding ambition in the region. The launch of Almirall’s eczema treatment, Ebglyss (lebrikizumab), generated $22 ...

Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

10/25, 根据周五在秋季临床皮肤病学 (FCD) 会议上公布的最新 IIIb 期数据，礼来公司（Lilly）$礼来(LLY)$最近获批的 IL-13 抑制剂 Ebglyss (lebrikizumab-lbkz) 在中度至重度特应性皮炎患者中表现出显著的皮肤清除和瘙痒缓解改善，这些患者之前已停用赛诺菲和再生元的 Dupixent (dupilumab)。 ADapt 研究的结果可能将 Ebgl ...

Probably the biggest objection to buying Lilly stock is its valuation. The big pharmaceutical company's shares trade at nearly 37.5 times forward earnings. Does this high multiple disqualify Lilly as ...

We achieved several key pipeline milestones this quarter, including the approval of Ebglyss in the U.S. for the treatment of moderate-to-severe atopic dermatitis. The approval of Kisunla in Japan ...

The company’s new products, including Ebglyss and Kisunla, reported a revenue increase of $3.07 billion, reaching $4.51 billion in Q3 2024. Mounjaro alone generated $3.11 billion in revenue, ...

Approvals included Ebglyss in the U.S. for moderate-to-severe atopic dermatitis and Kisunla in Japan for early symptomatic Alzheimer's disease. Positive Phase 3 data included the 176-week study of ...